Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study

Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the precise consequences of targeting immune cell trafficking for immunoregulatory network functions are only incompletely...

Full description

Bibliographic Details
Main Authors: Lisa Lohmann, Claudia Janoschka, Andreas Schulte-Mecklenbeck, Svenja Klinsing, Lucienne Kirstein, Uta Hanning, Timo Wirth, Tilman Schneider-Hohendorf, Nicholas Schwab, Catharina C. Gross, Maria Eveslage, Sven G. Meuth, Heinz Wiendl, Luisa Klotz
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
cerebrospinal fluid
natalizumab
fingolimod
viSNE
spanning-tree progression analysis of density-normalized events
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01560/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01560/full

Similar Items